Solid Biosciences Inc. (SLDB) SEC Filings & Earnings Calls

Dilution risk from large equity offering; pre-revenue company with high cash burn.

“up to $200.0 million of shares of common stock” · word for word

Clinical trial failure risk

“We have never completed a clinical trial and may be unable to do so for any Candidate, including SGT-003, SGT‑212, SGT-501 and other Candidates.” · word for word

Need for additional funding

“We will need additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.” · word for word

Novel technology risk

“Our pipeline of gene transfer candidates, which we refer to collectively as our Candidates, utilize novel technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval.” · word for word

Pre-revenue gene therapy company; history of operating losses; accumulated deficit $1.0B.

“As of March 31, 2026, we had an accumulated deficit of $1.0 billion.” · word for word

Clinical hold history; potential for future holds.

“One of our prior clinical trials had been placed on clinical hold by the FDA in the past, and we cannot guarantee that similar events will not happen in ongoing, planned and future clinical trials for our Candidates.” · word for word

Novel gene therapy technology; limited approved products.

“Our pipeline of gene transfer Candidates utilize novel technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval. To our knowledge, only a limited number of gene transfer products have been approved for commercialization in the United States and the European Union.” · word for word

Need for additional funding; cash runway only into first half of 2028.

“We will need additional funding, which may not be available on acceptable terms, or at all.” · word for word

Dilution risk from authorized share increase

“The approval of an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 240,000,000 to 480,000,000” · word for word

Continued net losses

“Net Income ($ Millions) 2025 (174.33) 2024 (124.70)”

Clinical development risk

“Our pipeline of gene transfer Candidates utilize novel technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval.” · word for word

Financial sustainability risk

“We have incurred significant net losses since inception and anticipate that we will continue to incur net losses for the foreseeable future and may never achieve or maintain profitability.” · word for word

Regulatory approval risk

“Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our Candidates and the approval may be for a narrower indication than we seek.” · word for word

Clinical trial risk: interim data based on small sample sizes (n=20 at Day 90, n=3 at Day 360) and may not be representative of full trial results; long-term safety and efficacy remain unproven.

“The interim clinical data reported is as of a February 23, 2026, data cutoff date. ... Results demonstrated robust mean vector copies per nucleus and microdystrophin expression ... (n=20 unless noted) ... (n=3).” · word for word

Dilution risk from private placement; pre-revenue company with high cash burn.

“Private Placement ... Shares and Pre-Funded Warrants”

Clinical trial risk; regulatory pathway uncertain; cash burn continues.

“Company does not expect that its existing cash ... will be sufficient to fund the completion of the development”